Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
1.3
0.9
Journals
Hemato
Sections
Exclusive Papers of the Editorial Board Members (EBMs) of Hemato
share announcement

Exclusive Papers of the Editorial Board Members (EBMs) of Hemato

A topical collection in Hemato (ISSN 2673-6357).

Viewed by 21087

Editors

Prof. Dr. Antonino Carbone

E-Mail Website
Guest Editor
Professor of Pathology, Former Chairman of Department of Pathology, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Aviano, Italy
Interests: hematopathology; Hodgkin lymphoma; non Hodgkin lymphoma; HIV-associated lymphoma; virus-associated lymphoma; post-transplant lymphoma; pathology; immunohistochemistry; tumour microenvironment; telepathology
Special Issues, Collections and Topics in MDPI journals
Dr. Laurent Garderet

E-Mail Website
Guest Editor
Service d'Hématologie, Hôpital Pitié Salpêtrière, 47‐83 boulevard de l'hôpital, F‐75013 Paris, France
Interests: myeloma; AL amyloidosis; monoclonal gammopathy of clinical significance; POEMS; transplantation
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

This Special Issue of Hemato is dedicated to recent advances in hematology, hematopathology, cellular biology, immunology, and molecular biology research areas and comprises a diverse selection of exclusive papers of the Editorial Board Members (EBMs) of Hemato. It focuses on highlighting recent interesting investigations conducted in the laboratories or clinics of our journal’s EBMs and represents our journal as an attractive open-access publishing platform for hematology-related research data.

Prof. Dr. Antonino Carbone
Dr. Laurent Garderet
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (5 papers)

Download All Papers

2021

Jump to: 2020

10 pages, 272 KiB  
Commentary
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2
by Jill Corre, Michele Sabbah, Fredrik Schjesvold, Amer M. Zeidan, Francesco Buccisano, David Sallman, Mario Mazzucato, Leigh A. Madden, Maurizio Martini, Eric Van Breda, Riccardo Dolcetti, Alessandro Busca, Gordon Cook, Francesco Onida, Annibale Versari, Jean-Jacques Kiladjian, Roland B. Walter, Laurent Garderet, Marie Robin and Alberto Signore
Hemato 2021, 2(1), 79-88; https://doi.org/10.3390/hemato2010004 - 9 Feb 2021
Cited by 1 | Viewed by 3154
Abstract
Recent Advancements in Hematology: Knowledge, Methods and Dissemination is a series of commentary article which is published on a biannual basis by the editorial board of the journal Hemato [...] Full article

2020

Jump to: 2021

17 pages, 2388 KiB  
Review
The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock
by Carolina Secreto, Alessandro Busca, Tommaso Lupia, Silvia Corcione and Francesco Giuseppe De Rosa
Hemato 2020, 1(2), 60-76; https://doi.org/10.3390/hemato1020010 - 25 Nov 2020
Cited by 4 | Viewed by 4269
Abstract
Bloodstream infection (BSI) and septic shock represent one of the major limiting factors for the successful treatment of patients affected by hematologic malignancies. During the most recent years we have documented a shift in the epidemiology of bacterial infections toward a consistent rise [...] Read more.
Bloodstream infection (BSI) and septic shock represent one of the major limiting factors for the successful treatment of patients affected by hematologic malignancies. During the most recent years we have documented a shift in the epidemiology of bacterial infections toward a consistent rise of Gram-negative rods. In addition, the emergence of multi-drug-resistant bacteria is considered a life-threatening condition requiring a multi-disciplinary approach. Aim of present review is to summarize the most recent approaches in terms of anti-microbial prophylaxis and treatment of BSI in hematologic patients with neutropenic fever. Full article
►▼ Show Figures

Figure 1

13 pages, 979 KiB  
Review
The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study
by Anne-Marie Rasmussen, Frida Bugge Askeland and Fredrik Schjesvold
Hemato 2020, 1(2), 36-48; https://doi.org/10.3390/hemato1020008 - 24 Sep 2020
Cited by 3 | Viewed by 4306
Abstract
The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time [...] Read more.
The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment. Full article
►▼ Show Figures

Figure 1

13 pages, 298 KiB  
Editorial
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
by Jude Fitzgibbon, Sophie Park, Gordon Cook, Bruno Paiva, Annunziata Gloghini, Eric Van Breda, Fabiana Busti, Laurent Garderet, Ricardo Dolcetti, Marie Robin, Rodrigo Martino, Alessandro Busca, Michèle Sabbah, Salvatore De Rosa, Maurizio Martini, Francesco Onida, Pierre Aucouturier, Fredrik Schjesvold, Stéphane Minvielle, Mario Mazzucato, Carolina Terragna, Michel Delforge, Claire Harrison and Antonino Carboneadd Show full author list remove Hide full author list
Hemato 2020, 1(1), 10-22; https://doi.org/10.3390/bloods1010005 - 1 Jul 2020
Viewed by 4891
Abstract
Recent Advancements in Hematology: Knowledge, Methods and Dissemination is a series of editorials which is published on a biannual basis by the editorial board of the journal Bloods [...] Full article
2 pages, 186 KiB  
Editorial
Recent Advancements in Hematology: Knowledge, Methods and Dissemination
by Jude Fitzgibbon, Alessandro Busca, Annunziata Gloghini, Armando López-Guillermo, Attilio Orazi, Carmelo Carlo-Stella, Emmanuel Andrès, Eric Van Breda, Fabiana Busti, Laurent Garderet, Maurizio Martini, Riccardo Dolcetti, Salvatore De Rosa, Sergio Siragusa, Teresa Marafioti and Antonino Carbone
Hemato 2020, 1(1), 5-6; https://doi.org/10.3390/bloods1010003 - 20 Mar 2020
Viewed by 2983
Abstract
Communication in the field of biomedical research today involves professionals of numerous backgrounds, including researchers, doctors, public administrators, politicians, and health journalists [...] Full article
Back to TopTop